Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05192382 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

A Phase 3 study of Acromegaly, sponsored by Crinetics Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
111
Enrollment target
20
Study locations

NCT05192382 is a Phase 3 study of Acromegaly that is active but no longer recruiting, run by Crinetics Pharmaceuticals. The registered enrollment target is 111 participants, above the 93-participant average among 13 other Acromegaly trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05192382, a Phase 3 study of Acromegaly, is active but no longer recruiting, sponsored by Crinetics Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
111 participants
Enrollment target
20
Study locations

Study Summary

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

Conditions Studied

Acromegaly

Interventions

  • DRUG Placebo
  • DRUG Paltusotine

Study Locations (20)

Other

  • Crinetics Study Site - Buenos Aires
  • Crinetics Study Site - CABA
  • Crinetics Study Site - CABA
  • Crinetics Study Site - Córdoba
  • Crinetics Study Site - Rio de Janeiro
  • Crinetics Study Site - São Paulo
  • Crinetics Study Site - São Paulo
  • Crinetics Study Site - Sofia

Pennsylvania

  • Crinetics Study Site - Philadelphia
  • Crinetics Study Site - Pittsburgh

São Paulo

  • Crinetics Study Site - Botucatu
  • Crinetics Study Site - Campinas

Colorado

  • Crinetics Study Site - Aurora

Massachusetts

  • Crinetics Study Site - Boston

Ohio

  • Crinetics Study Site - Columbus

Oregon

  • Crinetics Study Site - Portland

Buenos Aires

  • Crinetics Study Site - CABA

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2021-12-17
Est. Completion 2028-01
Phase Phase 3

Sponsor

Crinetics Pharmaceuticals

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05192382

The ClinicalTrials.gov registry entry for NCT05192382 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 13 other Acromegaly trials with a reported enrollment target (19% higher). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05192382 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Pennsylvania, São Paulo.

Frequently Asked Questions

What is clinical trial NCT05192382 about?

NCT05192382 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)". A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

What is the current status of trial NCT05192382?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2021-12-17. Estimated completion is 2028-01.

What conditions does trial NCT05192382 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT05192382?

The interventions under investigation include: Placebo (DRUG), Paltusotine (DRUG).

Who is sponsoring clinical trial NCT05192382?

This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05192382 being conducted?

This trial has 20 study locations across Colorado, Massachusetts, Ohio, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acromegaly

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.